Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response
Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease
Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival
Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients
Breast Cancer Risk Increases With Repeated CT Imaging
Scatter Radiation from Mammography Presents No Increased Cancer Risk
MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies
Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas
NCI-Approved CTEP Trials For the Month of December
FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- What will Trump’s return to the White House mean for oncology?
“Our work just got a lot more difficult.” - Menin inhibitors emerge as new treatment for advanced AML
- Kaklamani: The San Antonio Breast Cancer Symposium will focus on deescalating treatment while maintaining outcomes
